Prof Simon Noble is a Clinical Senior Lecturer in Palliative Medicine. He also holds an honorary consultant post with the Royal Gwent Hospital in Newport. His main research interests are in the management of venous thromboembolism in advanced cancer and the anticancer effects of heparins. He is involved at a national level in the delivery of evidence based thromboprophylaxis for hospitalised patients through the All Party Thrombosis Group and the UK Thromboprophylaxis Forum. He is Trustee and Medical Director (Wales) for Lifeblood: the Thrombosis Charity and is currently chairing the All Wales Thromboprophylaxis Group.
He is co investigator for FRAGMATIC a multicentre randomised control trial to investigate the impact of dalteparin on survival in lung cancer. This study aims to recruit 2200 patients. He is also co investigator in T-FRAG; a translational sub study and QUAL FRAG a qualitative sub study. He is co-director of the Thrombosis Research in Advanced Disease Alliance (TRAD Alliance) a joint venture with Hull York Medical School, which is involved in developing thrombosis studies in the palliative care population. He chairs the WCTU / SEWTU Thrombosis Research Group.
Steve is the co-lead of the Early Phase Clinical Trials work package. He is an academic clinical haematologist and combines the role of Clinical Senior Lecturer in the Institute of Cancer and Genetics at Cardiff University School of Medicine with clinical work as an Honorary Consultant Haematologist at the University Hospital of Wales where he serves as haematological cancer lead clinician.
Steve's clinical practice is predominantly in myeloid haematological cancers, particularly acute myeloid leukaemia, the myeloproliferative neoplasms and myelodysplastic syndromes. His chief research interest lies in the development of targeted therapeutic agents in myeloid malignancies; this includes pre-clinical laboratory studies of FLT3 inhibition, TAM-kinase inhibition and reactive oxygen species manipulation and clinical research including 'back-to-bench' laboratory projects running alongside clinical trials.
Steve is extensively involved in the development of clinical research at a national level through membership of the UK NCRI AML and Myeloproliferative Neoplasms Clinical Study Groups. He is chief investigator of Monocle - a UK study of tefinostat in chronic myelomonocytic leukaemia, and co chief investigator of the AML18 and AML LI-1 trials. His other roles include Cardiff lead for the Leukaemia Lymphoma Research (now Bloodwise) Trials Acceleration Programme and lead of Cardiff School of Medicine medical undergraduate haematology teaching.